Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials

Abstract

What is already known on this topic What is already known on this topic Episodes of acute rejection reduce graft survival in patients with renal transplants Increasing immunosuppression to reduce rejection can increase infection and malignancy What this study adds What this study adds Addition of interleukin-2 receptor antibodies to ciclosporin based immunosuppression regimens halves the risk of acute rejection Patients receiving antibodies did not have an increased risk of infection The effects on graft loss and mortality at one year were not significant What is already known on this topic What is already known on this topic Episodes of acute rejection reduce graft survival in patients with renal transplants Increasing immunosuppression to reduce rejection can increase infection and malignancy What this study adds What this study adds Addition of interleukin-2 receptor antibodies to ciclosporin based immunosuppression regimens halves the risk of acute rejection Patients receiving antibodies did not have an increased risk of infection The effects on graft loss and mortality at one year were not significant